Time-From-Diagnosis Subgroups

POST HOC ANALYSIS: Time-from-diagnosis Subgroups UPTRAVI Reduced Risk of Disease Progression When Used Within 6 Months of Diagnosis vs Placebo1-4

The information below is from a post hoc subgroup analysis of the GRIPHON trial.
View the GRIPHON pivotal data for context of the overall population.

POST HOC ANALYSIS: TIME-FROM-DIAGNOSIS SUBGROUPS 53% RISK REDUCTION OF DISEASE PROGRESSION WHEN UPTRAVI USED WITHIN 6 MONTHS OF DIAGNOSIS VS PLACEBO1-4

Baseline patient characteristics

  • GRIPHON patients were categorized based on their time from diagnosis at baseline using a 6-month threshold:
    • 35% (n=404) of all patients in GRIPHON were treated ≤6 months from diagnosis (52% FC II and 46% FC III)*
  • 41% were receiving PDE-5i monotherapy, 39% were receiving no background PAH therapy, 10% were receiving ERA monotherapy, and 10% were receiving an ERA + PDE-5i at baseline

Notable differences in baseline characteristics from overall population

Patients in the ≤6 months from diagnosis subgroup were:

  • Younger
  • More likely to be in FC II
  • More likely to be treatment naïve or receiving PDE-5i monotherapy
  • More likely to be from Asia/Eastern Europe
Time to first disease progression event in patients treated within 6 months of PAH diagnosis
Events in patients treated within 6 months of PAH diagnosis1

Adverse reactions in ≤6 months from diagnosis subgroup notably different from overall population

  • Irrespective of time from diagnosis, the most frequently reported adverse reactions for patients treated with UPTRAVI were headache, diarrhea, and nausea3

POST HOC ANALYSIS: TIME-FROM-DIAGNOSIS SUBGROUPS 26% RISK REDUCTION OF DISEASE PROGRESSION WHEN UPTRAVI USED AFTER 6 MONTHS OF DIAGNOSIS VS PLACEBO1-4

Baseline patient characteristics

  • GRIPHON patients were categorized based on their time from diagnosis at baseline using a 6-month threshold:
    • 65% (n=752) of all patients in GRIPHON were treated >6 months from diagnosis (56% FC III, 42% FC II)*
  • 28% were receiving PDE-5i monotherapy, 11% were not receiving PAH background therapy, 17% were receiving ERA monotherapy, and 15% were receiving an ERA + PDE-5i at baseline

Notable differences in baseline characteristics from overall population

Patients in the >6 months from diagnosis subgroup:

  • Were more likely to be from Western Europe/Australia and North America
  • Had a longer mean time from diagnosis
  • Were more likely to be receiving ERA + PDE-5i
Time to first disease progression event in patients treated after 6 months of PAH diagnosis
Events in patients treated within 6 months of PAH diagnosis1

Adverse reactions in time-from-diagnosis subgroups notably different from overall population

  • Irrespective of time from diagnosis, the most frequently reported adverse reactions for patients treated with UPTRAVI were headache, diarrhea, and nausea3